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Abstract 
Background 
LCHADD is along-fatty acid oxidation disorder with immediate symptoms and long-term 
complications. We evaluated data on clinical status, biochemical parameters, therapeutic 
regimens and outcome of Austrian LCHADD patients. 
Study design 
Clinical and outcome data including history, diagnosis, short- and long-term manifestations, 
growth, psychomotor development, hospitalizations, therapy of 14 Austrian patients with 
LCHADD were evaluated. Biochemically, we evaluated creatine kinaseacyl carnitine 
profiles. 
Results 
All LCHADD patients are homozygous for the common mutation. Three are siblings. 
Diagnosis was first established biochemically. Nine/14 (64%) were prematures, with IRDS 
occurring in six. In nine (64%), diagnosis was established through newborn screening, the 
remaining five (36%) were diagnosed clinically. Four pregnancies were complicated by 
HELLP syndrome, one by preeclampsia. In two, intrauterine growth retardation and placental 
insufficiency were reported. Five were diagnosed with hepatopathy at some point, seven with 
cardiomyopathyand eight with retinopathy, clinically relevant only in one patient. 
Polyneuropathy is only present in one. Three patients have a PEG, one is regularly fed via 
NG-tube. Growth is normal in all, as well as psychomotor development, except for two 
extremely premature girls. In 11 patients, 165 episodes with elevated creatine kinase 
concentrations were observed , with 6-31 (median 14) per patient; three have shown no 
elevated CK concentrations. Median total carnitine on therapy was 19 µmol/l (range 11-61). 
For 14 patients, there have been 181 hospitalizations (median 9 per patient), comprising 1337 
in-patient-days. All centres adhere to treatment with a fat-defined diet; patients have between 
15% and 40% of their energy intake from fat (median 28.5%), out of which between 20% and 
80% are medium-chain triglycerides (MCT) (median 62%). Four patients have been treated 
with heptanoate. 
Conclusion 
Our data show LCHADD outcome can be favourable. Growth and psychomotor development 
is normal, except in two prematures. Frequency of CK measurements decreases with age, 
correlating with a decreasing number of hospitalizations. About 50% develop complications 
affecting different organ systems. There is no relevant difference between the patients treated 
in the respective centers. Concluding from single case reports, anaplerotic therapy with 
heptanoate should be further evaluated . 
Keywords 
Long-chain 3-hydroxy acyl CoA dehydrogenase deficiency, Outcome, Clinical course, Long-
term complications, Children 
Background 
Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD) (OMIM #609016) is 
an autosomal recessively inherited disorder of long-chain fatty acid oxidation with an 
estimated overall frequency of 1:50,000, first described in 1989 in children presenting with 
hypoketotic hypoglycemia and lethargy after periods of fasting, often associated with febrile 
infections and gastroenteritis [1,2]. LCHAD is part of the mitochondrial trifunctional protein 
(MTP) and specific for the metabolism of C12-C16 chain-length fatty acid compounds. 
LCHADD leads to an accumulation of toxic β-oxidation intermediates causing immediate 
symptoms as well as long-term complications. It was included in the Austrian newborn 
screening program in April 2002. An association between maternal HELLP syndrome, 
prematurity and fetal LCHADD has been previously published [3-5]. Clinical symptoms 
mainly develop during episodes of illness or fasting and affect organs needing long-chain fat 
as primary energy source such as heart and skeletal muscle [6-8]. Impaired glucose 
production during catabolism results in hypoketotic hypoglycemia [9]. Therapy aims at 
defining the intake of exogenous long-chain fatty acids as well as preventing catabolic 
episodes, which lead to energy mobilization out of endogenous fat [10]. Anaplerotic therapy 
with e.g. heptanoate is based on the concept of providing an odd-carbon numbered substrate 
for the citric acid cycle and the electron transport chain that bypasses the deficient fatty acid 
oxidation (FAO) enzymes in order to enhance ATP production. Significant relief of FAOD-
related clinical symptoms such as hypertrophic cardiomyopathy, congestive heart failure, 
hepatomegaly and muscle weakness has been reported in VLCADD patients with a diet 
containing 30-35% of total caloric intake as heptanoate [11]. 
Although LCHADD is a fatty acid oxidation disorder with significant morbidity, information 
on the development and outcome is still rather limited. 
Therefore, we collected data of the 14 living Austrian patients with LCHADD, including 
clinical status, biochemical parameters, therapeutic regimens and outcome. 
Methods 
Study population 
We retrospectively collected data of 14 living patients with LCHADD, cared for in four 
Austrian (Graz, Innsbruck, Salzburg, Vienna) and one German (Munich) metabolic center. 
Data of all 14 patients were reviewed at their respective metabolic center from birth until 
October 2013. Thus, follow-up times were between 0.9 and 15.4 years (median 7.8 years, 
mean 6.9 years). The 14 patients come from 11 families and include 3 siblings of 
consanguineous parents (Patient 5, 13, 14). Details of the study cohort are displayed in Table 
1. All patients have biochemically confirmed LCHADD and are homozygous for the 
common mutation c.1528G > C. In ten, the diagnosis was confirmed enzymatically in 
fibroblasts. 
Table 1 Background data of the study cohort 
Patient (Metabolic center) Gender Current age (y) Age at diagnosis NBS+ Decom-pensation at diagn. Pregnancy Birth mode GA 
Patients born before introduction of LCHADD into NBS program, diagnosed clinically 
1 (Munich) M 15.3 5 m no* yes HELLP CS 37 weeks 
2 (Innsbruck) M 14.1 23 m no* yes normal CS 38 weeks 
3 (Graz) F 12.2 3 m no* yes normal vaginal Term 
Patients born after introduction of LCHADD into NBS program (group 1-3): 
Group 1: Patients showing symptoms before NBS results were available: 
4 (Innsbruck) F 7.8 15 d yes (yes) IUD CS 32 weeks 
5 (Vienna) M 7.3 15 d yes (yes) normal vaginal 35 weeks 
6 (Innsbruck) M 2.7 15 d yes (yes) IUD CS 32 weeks# 
Group 2: Patients with false negative NBS results: 
7 (Graz) M 10.6 4 m no** yes HELLP CS 31 weeks# 
8 (Salzburg) M 5.2 5 m no** yes HELPP CS 29 weeks# 
Group 3: Patients with positive NBS results, asymptomatic: 
9 (Vienna) F 10.8 1 d Yes no normal vaginal Term 
10 (Vienna) F 9.5 6 d Yes no twin pregnancy CS 29 weeks# 
11 (Graz) F 3.7 1 d yes no HELLP CS 32 weeks# 
12 (Vienna) M 2.8 10 d Yes no preeclampsia CS 34 weeks 
13 (Vienna) F 2.7 1 d Yes no path. CTG CS 25 weeks# 
14 (Vienna) M 0.9 2 d Yes no normal vaginal 40 weeks 
Summary for the 14 LCHADD patients: 
 8 M/6 F median: 7.6 y median:15 d NBS + 9/14 8/14 4/14 HELLP CS 10/14 9/14 preterm 64%; 6/9 IRDS 
range: 0.9-15.3 range: 1d-20 m 64% 57% 1/14 preecl. 71% 
Table shows patient number and treating center, gender, current age (referring to October 2013), age at diagnosis, newborn screening result, decompensation at time of 
diagnosis, pregnancy, birth mode, and gestational age. 
Patients are grouped by mode of diagnosis, either born before or after introduction of LCHADD into NBS program. 
(NBS+) diagnosis through newborn screening; (GA) gestational age; (C7) therapy with triheptanoate; (M) male; (F) female; (y) years; (m) months; (d) days; (IUD) 
intrauterine dystrophy, following placental insufficiency; (HELLP) hemolysis, elevated liver enzymes, low platelet count syndrome; (path. CTG) pathological CTG, 
bradycardia; (CS) Caesarean section. *born before LCHADD was included into Austrian Newborn-Screening program, **newborn screening false negative, probably due to 
prematurity; #IRDS present; (IRDS) infant respiratory distress syndrome. 
Data collection 
We collected clinical information by review of medical records. Besides epidemiological data 
(Table 1), we evaluated: growth, short and long term complications, number of hospital 
admissions and length of stay (in days per year); creatine kinase concentrations (peak levels) 
as a marker for rhabdomyolysis, and two acyl carnitine profiles per patient (one at diagnosis 
and last one available). Fat intake and quality of fats was evaluated with available dietary 
protocols; and information on PEG/NG tube feeding, late evening feeds, bolus before sports, 
as well as concomitant medications was retrieved. 
The study was conducted with the approval of the ethics committee of the Medical University 
of Innsbruck. Research was carried out in compliance with the Helsinki Declaration. Parents 
gave their consent for this retrospective data collection. 
Statistics 
As the cohort is significant for a rare disorder but rather small in principle, only descriptive 
statistical analyses were performed. 
Results 
Diagnosis and onset of symptoms 
Nine/14 patients were diagnosed by newborn screening, three/nine showing clinical 
symptoms before results were available (Patient 4, 5, and 6) (Table 1). In two additional ones 
(Patient 7 and 8) newborn screening was false negative, probably due to prematurity and L-
carnitine supplementation (Table 1). The other three (Patient 1, 2, 3) were born before the 
inclusion of LCHADD into the newborn screening panel and were detected through 
metabolic decompensation at 5 months, 23 months, and 3 months of age, respectively (Table 
1) with metabolic acidosis, hepatopathy, cardiomyopathy, rhabdomyolysis; and coma in 
Patient 2. 
Nine/14 patients were born prematurely (Table 1), postpartally, six of them showed IRDS, 
and three inguinal hernia (Patient 6, 7, 11). Four pregnancies were complicated by HELLP 
syndrome and one by preeclampsia (Table 1). 
Clinical signs – short and long term organ involvement 
All patients are in a stable clinical condition and have normal growth. At some point, 5/14 
patients have shown hepatopathy defined as a sonographic finding and elevated liver enzyme 
tests (range 0-23 months, median 4), and 7/14 cardiomyopathy defined as fraction shortening 
(FS) <25 and/or ejection fraction (EF) <50 in at least one echocardiographic screening (range 
3-156 months, median 5). Retinopathy has been reported in 8/14, however, only one (Patient 
3) suffers from severe impairment of vision. Polyneuropathy has been reported only in the 
oldest patient so far (Patient 1), with onset at 9 years (Table 2). 
Table 2 Clinical signs – short and long term organ involvement in the 14 Austrian patients with LCHADD and when firstly diagnosed in 
months of age 
Patient Current age (y) Hepatopathy CMP Retinopathy NG/PEG Late night feeds 
Patients born before introduction of LCHADD into NBS program, diagnosed clinically 
1 15.3  156 m 108 m PEG 24 m X* 
2 14.1 23 m 23 m 23 m  X 
3 12.2 3 m 3 m 24 m   
Patients born after introduction of LCHADD into NBS program (group 1-3): 
Group 1: Patients showing symptoms before NBS results were available: 
4 7.8      
5 7.3   39 m   
6 2.7  9 m    
Group 2: Patients with false negative NBS results: 
7 10.6 4 m 4 m 42 m   
8 5.2 5 m 5 m 38 m PEG 12 m X* 
Group 3: Patients with positive NBS results, asymptomatic: 
9 10.8   50 m   
10 9.5  4 m 56 m PEG 11 m X 
11 3.7    NG 7 m  
12 2.8     X 
13 2.7 neonatally    X 
14 0.9     X 
Summary for the 14 LCHADD patients: 
  36% 50% 57% 29% 50% 
Patients grouped by mode of diagnosis (see Table 1). Cardiomyopathy in Patient 1, 2, 3, 6, 7, 8, 10 is defined as fractional shortening (FS) <25 and/or ejection fraction (EF) < 
50 in at least one echocardiographic screening, Patient 3 showed a prolonged QTc interval of 0.45 msec (0.42 +/- 0.02); retinopathy as described in fundoscopy reports, 
hepatopathy defined as a sonographic finding and elevated liver enzyme tests. Current age (referring to October 2013), (y) years; (m) months; (CMP) cardiomyopathy; (NG) 
nasogastric tube; (PEG) percutaneous endoscopic gastrostomy. Late evening meal, usually 22:00; X* - continuous night drip feeding via PEG. 
Creatine kinase 
In 11 patients, there have been 165 episodes with elevated creatine kinase concentrations 
(sign of muscle involvement / rhabdomyolysis (defined as CK levels > 1,000 U/l, range 
1,000-95,000, median 40,381). The range per patient is 6-31 episodes (median 14) (Table 3). 
In three patients no elevated CK concentrations (>1,000 U/l) have been measured so far. For 
14 patients, there are a total of 722 CK (range 9-132 per patient) measurements available 
(Table 3). 
Table 3 Features of creatine kinase in 14 patients with LCHADD - Patients grouped by 
mode of diagnosis (see Table 1 and 2) 
Patient n CK max CK max CK n CK >1,000 
(in U/l) (age) (in U/l) 
1 57 40,381 16.2 y 19 
2 127 34,160 4.2 y 31 
3 36 39,501 5.8 y 10 
4 132 10,170 1.9 y 19 
5 67 8,876 3.9 y 17 
6 15 299 0.8 y 0 
7 52 62,216 2.7 y 6 
8 69 73,260 0.9 y 27 
9 22 95,000 2.7 y 8 
10 71 67,500 2.6 y 14 
11 29 68,600 0.6 y 6 
12 26 12,000 2.1 y 8 
13 9 449 1.7 y 0 
14 10 725 2 d 0 
Median 44 40,381 2.35 y 14 
(n CK) number of CK measurements, (max CK (in U/l)) highest measured CK, (max CK (age)) age when 
highest CK was measured, (n CK > 1,000) number of CK measurements >1,000 U/l, (y) years. 
Total carnitine and acyl carnitine profiles 
Carnitine state and acyl carnitine profiles were collected at the time of diagnosis and last 
analysis available (Table 4). At the time of diagnosis, which ranges from 1 day to 20 months 
(median 15 days), median total carnitine was 44 µmol/l (range 10-118), free carnitine 19 
µmol/l (range 3-97), C16OH 0.4 µmol/l (range 0.2-1.1), C18:1OH 0.5 µmol/l (range 0.1-1.2), 
and C18OH 0.4 µmol/l (range 0.2-0.8). Three prematures were being treated with L-carnitine. 
At the time of last acyl carnitine profile available, which ranges from 0.3 to 15 years (median 
7), median total carnitine was 19 µmol/l (range 11-61), free carnitine 10 µmol/l (range 6-46), 
C16OH 0.3 µmol/l (range 0.1-0.5), C18:1OH 0.4 µmol/l (range 0.1-0.7), and C18OH 0.3 
µmol/l (range 0.1-1.0). No patient is being treated with L-carnitine. In summary, 
concentrations are generally lower after diagnosis is known. There is no correlation between 
acyl carnitine concentrations and age. 
Table 4 Acylcarnitine profiles from 14 Austrian LCHADD patients at diagnosis and at last follow-up 
 Acylcarnitine profile at diagnosis Acylcarnitine profile at last follow-up 
Patient age at diagn. TC C0 C16OH C18:1OH C18OH age at last follow-up TC C0 C16OH C18:1OH C18OH 
1 5 m - 5 0.57 1.19 0.39 15.0 y - 39 0.19 0.22 - 
2 23 m 21 3 0.17 0.08 - 13.5 y 18 11 0.16 0.17 0.23 
3 3 m - 11 0.69 0.54 - 9.0 y 32 25 0.01 0.05 0.10 
4 *15 d 45 27 0.30 0.50 0.20 7.2 y 14 9 0.37 0.44 1.00 
5 15 d 42 20 0.20 0.16 0.40 6.8 y 18 10 0.11 0.49 0.54 
6 *15 d 91 45 0.48 0.62 0.50 2.1 y 15 7 0.42 0.66 0.78 
7 4 m 10 5 0.24 0.66 - 9.0 y 45 37 - 0.01 0.01 
8 5 m 17 9 0.98 0.74 - 3.6 y 48 28 0.25 0.11 0.24 
9 1 d 13 8 0.82 - 0.49 8.6 y 11 6 0.31 0.65 0.41 
10 6 d 118 97 0.35 - 0.80 8.7 y 17 10 0.12 0.10 0.20 
11 1 d 77 33 - - - 3.2 y 61 46 0.13 - - 
12 *10 d 103 56 0.25 0.37 0.34 2.2 y - - 0.31 0.42 0.35 
13 1 d 39 18 0.21 0.27 0.30 2.1 y 20 10 0.52 0.69 0.95 
14 2 d 68 32 1.1 0.41 0.69 0.3 y 22 10 0.53 0.40 0.47 
Median 15 d 44 19 0.35 0.50 0.40 7.0 19 10 0.25 0.40 0.30 
Range 1d-20 m 10-118 3-97 0.17-1.1 0.08-1.19 0.2-0.8 0.3-15.0 11-61 6-46 0.01-0.53 0.01-0.69 0.01-1.0 
Patients grouped by mode of diagnosis (see Table 1 and 2). 
Concentrations in µmol/l. TC total carnitine; C0 free carnitine, C16OH 3-hydroxyhexadecanoylcarnitine; C18:1OH 3-hydroxyoctadecenoylcarnitine, C18OH3-
hydroxyoctadecanoylcarnitine; d days; m months; y years. 
Reference values are: TC 7-70 µmol/l, C0 6-54 µmol/l, C16OH < 0.12 µmol/l, C18:1OH < 0.16 µmol/l, C18OH < 0.13 µmol/l, (-) no values given in laboratory report. 
*patients receiving carnitine therapy as prematurity treatment. 
PEG / NG tube feeding / late evening feeds / bolus before sports / concomitant 
medication 
Ten/14 patients eat self-sufficiently, three have a PEG (Patient 1, 8, and 10) and one is being 
regularly fed via nasogastric tube (Patient 11), all four presented with regular vomiting and 
refusal of oral feeds with somatic reasons being excluded. Patient 10 has a reflux diagnosed 
with 10 months. PEG were installed at 12 (Patient 8), 11 months (Patient 10) and 24 months 
(Patient 1) of age and have been in place for 4.7, 8.6 and 13 years, respectively. Patient 11 
still shows very little interest in food and receives most of her caloric intake in form of a 
MCT formula (Monogen®) via NG tube. Patient 8 has improved from absolute refusal of oral 
feeds to occasional savoring of food samples by seeing a speech therapist. Of the 14 patients, 
six are reported to have late evening meals regularly, usually around 22:00, in additional two 
(Patient 1, 8), PEG is used for continuous night drip feeding (Table 2). 
Only Patient 2 is reported to regularly take a calorie bolus before exercise (sports) [12], and 
only two receive additional long term medication; Patient 7 due to allergic asthma, and 
Patient 1 cardiomyopathy treatment (diuretics and ramipril). 
Hospitalizations 
There have been 181 hospitalizations for 14 patients (range 2-34, median 9), comprising 1337 
in-patient-days (range per patient 23-247, median 78) (Table 5). Except for three patients, the 
first hospitalization is the longest, often involving LCHADD unrelated problems, like i.e. 
prematurity. With increasing age, hospitalizations become less frequent (Table 6). 
Table 5 Number of hospitalizations in 14 Austrian LCHADD patients 
Patient 1st hospitalization and time of LCHADD 
diagnosis 
Length of 1st hospitalization 
(days) 
Number of hospitalizations including 1st 
hospitalization 
Length of hospitalizations 
(total days) 
Range (days) Median (days) 
1 age 5 months 16 8 79 1-23 7 
2 23 months 26 18 76 1-26 2 
3 3 months 22 7 48 2-22 3.5 
4 GA 32 weeks 29 34 114 1-29 3 
5 GA 35 weeks positive family history  17 77 1-10 3 
6 GA 32 weeks 36 6 16 2-36 3 
7 GA 31 weeks; Dg. LCHADD 4 months 46 17 168 2-46 4 
8 GA 29 weeks 26 22 181 2-29 4 
9 NBS  6 22 1-9 4 
10 GA 29 weeks 89 23 247 1-89 8 
11 GA 32 weeks 55 10 94 1-55 3 
12 GA 34 weeks 23 6 27 3-23 4 
13 25 weeks 91 2 94 3-91 47 
14 NBS positive family history 6 2 23 6-17 11.5 
median  27.5 9 78   
range  6 – 91 2 – 34 16 – 247   
Patients grouped by mode of diagnosis (see Table 1 and 2). 
As the first hospitalization is often combined with other LCHADD independent causes, e.g. prematurity, it is listed separately. Except for Patient 7, first hospitalization and 
time of diagnosis are the same. 
Table 6 Hospitalizations; days / stays per patient (y-axis) and year of life (x axis; Y1, 
year 1 defined as 0-12 months; Y2, year 2 defined as 12-24 months, etc.) 
Patient Y1 Y2 Y3 Y4 Y5 Y6 Y7 Y8 Y9 Y10 Y11 Y12 Y13 Y14 Y15 
1 39/2    1/1  3/1     19/1  11/2 6/1 
2 0/0 26/1 13/4 14/3 20/7 3/2 0 0 0 0 1/1 0 0 0  
3 33/3 5/2 4/1   3/1 3/1  
4 45/7 26/6 18/3 21/7 4/2 10/3 13/4 6/2  
5 11/3 18/5 2/1 13/2 5/1 6/2 22/3  
6 50/5 2/1  
7 109/5 22/4 2/1  12/3 3/1 20/3  
8 94/8 59/8 20/5 5/2 3/1  
9 4/1 5/1 9/1 0 0 5/2 0 0 0 4/1  
10 176/13 48/4 14/3 4/1 0 0 0 5/2 0  
11 84/6 1/1 3/1 6/2  
12 0 10/2 17/4  
13 91/1 0 3/1  
14 23/2  
Long-term management - diet 
At the time of last dietary protocol available, which ranges from 0.9 to 15 years (median 5.6), 
all 14 patients are on a fat defined diet, with a median fat intake from total energy of 28.5% 
(range 15 – 40), and thereof a median MCT intake of 62% (range 20 – 80). For 
supplementation of long-chain essential fatty acids, 13 receive walnut oil (median 0.3 g/kg/d, 
range 0.1 – 0.8), Patient 1 does not. Additional DHA supplementation is given to 10/14 
patients. 
Heptanoate 
Four patients have been treated with heptanoate (Patient 2,4,6,8), which they have been 
receiving for different periods of time (13 months,13 months, 7 years and 9.4 years). In 
Patient 2, the dosage equals 0.6 g/kg/day, in Patient 4, 0.8 g/kg/day, in Patient 6, 0.75 
g/kg/day, in Patient 8, 0.6 g/kg/day (Table 7). Patient 8 discontinued C7 after 13 months, 
because no essential difference was appreciated by parents and care takers. 
Table 7 Dietary treatment in the 14 Austrian patients with LCHADD, calculated from a dietary protocol 
Patient age at evaluation Body weight (kg) Total fat intake % MCT of fat in diet Walnut oil (in ml and g/kg/d) Heptanoate (C7) (in ml and g/kg/d) C7 since DHA suppl. kcal/d 
1 15.0 y 72,6 30% 20% 0 ml -  +267 mg 3000 
2 13.5 y 55.5 40% 50% 5 ml = 0.10 30 ml = 0.60 9.4 y - 1800 
3 10.0 y 29.7 33.5% 72% 10 ml = 0.34 -  +89 mg 1700 
4 7.2 y 24.9 25% 52% 10 ml = 0.40 20 ml = 0.80 7 y - 1738 
5 7.3 y 29.0 27% 56% 3 ml = 0.10 -  *200 mg 1653 
6 2.7 y 13.3 36% 47% 6 ml = 0.45 10 ml = 0.75 16 m - 953 
7 10.6 y 36.9 29% 69% 10 ml = 0.27 -  +89 mg 1900 
8 # 4.0 y 17.4 15% 80% 10 ml = 0.57 10 ml = 0.60 13 m - 1452 
9 10.7 y 25.0 21% 68% 2 ml = 0.08 -  *200 mg 1850 
10 9.3 y 25.1 28% 70% 13 ml = 0.52 -  *100 mg 1782 
11 3.7 y 15.4 25% 64% 13 ml = 0.84 -  +89 mg 1300 
12 2.8 y 15.3 30% 63% 4 ml = 0.26 -  *100 mg 1377 
13 2.7 y 11.1 30% 61% 3 ml = 0.27 -  *150 mg 1166 
14 0.9 y 8.62 33% 65% 3 ml = 0.35 -  *150 mg 862 
median 5.6 y  28.5% 62% 0.34     
 0.9 – 15.0  15 – 40 20 – 80 0.08 – 0.84     
Amount of fat in diet, % MCT (middle chain triglycerides) in diet, walnut oil and C7 intake in ml and g/kg/day, *DHA supplementation: Key Omega ® 4 g sachet, 
containing 100 mg DHA; + 1 fish oil capsule, containing 89 mg DHA. #Patient 8 received C7 from age 3.75 until age 5 in an amount of 10 ml/d (=0.6 g/kg/d). (y) years; (m) 
months.
After heptanoate was started, we observed a better clinical stability and no more CK peaks in 
Patient 2 [12], therefore we compared outcome of the patients that receive heptanoate (Figure 
1). No statistical differences can be seen, however Patients 2,4,6 appear clinically more 
stable, and parents will not discontinue heptanoate treatment. Patient 4 did show episodes of 
rhabdomyolysis (CK max 10,170 U/l), but her CK levels were never as high (Figure 1). 
Before heptanoate was started, Patient 6 needed repeated hospitalizations during infections 
with marked hepatopathy, he now seems clinically more stable. CK concentrations have not 
shown significant changes – there never was a CK measured above 1,000 U/l, but the 
transaminases seem to stabilize (see Figure 1). In Patient 8 with failure to thrive, heptanoate 
was started with 45 months, and discontinued after 13 months because of stomache aches and 
diarrhea, which he also had prior to C7 supplementation. 
Figure 1 CK and liver enzymes in the four patients treated with heptanoate (start 
marked with red arrows). a: CK concentrations in Patient 2 before and after the 
introduction to therapy with heptanoate. b: CK concentrations and start of heptanoate in 
Patient 4. c: CK concentrations (left) and liver enzymes tests (right) before and after 
introduction of heptanoate in Patient 6. d: CK concentrations and start of heptanoate in 
Patient 8. 
Discussion 
In this retrospective data analysis of the 14 living Austrian patients with LCHADD, we 
wanted to collect and evaluate clinical status, biochemical parameters, therapeutic regimens 
and outcome. 
In literature, we found a total of 196 cases of LCHADD reported [7,8,13-27]; it must be 
assumed that some patients are reported repeatedly (i.e. Gillingham [10,16-18]). DenBoer et 
al. looked at similar parameters as we did (e.g. clinical, biochemical and therapeutic follow-
up of patients with isolated LCHADD) [7]. Other studies either included other fatty acid 
oxidation disorders or focused on more narrow and specific questions concerning patient 
development, such as for example growth, ophtalmological findings or metabolic control 
during exercise [18,20,27]. 
In contrast to data evaluation out of patient charts, DenBoer et al. sent out a standardized 
questionnaire to referring physicians of 61 unselected patients with LCHADD, 50 
questionnaires (82%) were returned [7]. Our 14 patients’ cohort reflects all living Austrian 
LCHADD patients, 8 male (57%) and 6 female (43%) patients, DenBoer’s cohort 23 male 
(46%) and 27 female (54%) patients. 
In our cohort, the median age of presentation was 15 days (range: 1 day to 23 months) for 
the whole cohort and 5 months (range 3 to 23 months) for the 5 patients not detected by 
newborn screening versus mean 5.8 months (range: 1 day to 26 months) in DenBoer’s cohort 
[7]. Four/14 pregnancies (28%) were complicated by HELLP syndrome in comparison to 
15% (7/47 pregnancies) observed by DenBoer [7]. 
All of DenBoer’s patients were diagnosed clinically, as LCHADD had not been included the 
Dutch Newborn Screening Program at the time the study was conducted. Patients showed 
hypoketotic hypoglycemia in 78%, chronic liver disease, failure to thrive, feeding difficulties 
/ hypotonia in 22%. In Austria, LCHADD was included in the NBS program in 2002, only 
patients that were born before (n = 3) or showed false negative results due to prematurity (n = 
2) were diagnosed clinically. However, from the ones with positive NBS results in our 
cohort, 3/9 patients were symptomatic before NBS results were available. However, they 
were not as severely diseased as the patients reported by DenBoer: Of these 39/50 presenting 
with acute metabolic derangement, 22 (56%) were comatous, 15 (38%) had seizures, 9 (23%) 
apneic spells, 8 (21%) cardiorespiratory arrest, 7 (18%) arrhythmias and 3 (9%) died death. 
These symptoms were not seen in our follow-up. In our cohort, only Patient 2 was found to 
be comatous at the point of first metabolic derangement. 
Long term complications are present in 36%-57% (Table 2). In summary, the 5 children 
diagnosed clinically (the three born before NBS was introduced) (Patient 1,2,3) and the two 
with false negative NBS results (Patient 7,8)), showed cardiomyopathy mostly at time of 
diagnosis. Four of these five diagnosed clinically have had hepatopathy, but only one/nine 
patients diagnosed by NBS. Retinopathy is present in the older patients, regardless of mode 
of diagnosis. However, as expected in this age group, the impact of retinopathy and 
polyneuropathy is low, with only one patient showing vision impairment and one patient 
having polyneuropathy. 
We did not focus on deceased LCHADD patients and do not have data concerning LCHADD 
mortality in Austria. The two deceased LCHADD patients close to the cohort were the the 
older sister of Patient 1 and the older brother of Patients 5, 13 and 14. 
Creatine kinase (CK) is an enzyme expressed in ATP consuming tissues, e.g. skeletal muscle 
and retinal photoreceptor cells, and is used as a marker of myocardial infarction, 
rhabdomyolysis, muscular dystrophy, autoimmune myositis and in acute renal failure [28,29]. 
In LCHADD patients it is used to determine rhabdomyolisis during metabolic derangement. 
CK determinations in our cohort (Table 3) show that CK is a reliable but unspecific marker. 
Episodes of rhabdomyolysis decrease with age, pointing to less infectious illnesses as 
expected in every child growing older. 
Acyl carnitine profile analysis is essential in the diagnosis of LCHADD. Acylcarnitine 
abnormalities in our cohort were consistent with those previously reported for LCHADD. 
Total long-chain acyl carnitines are used for clinical purposes [17], and should not exceed 2 
µmol/l. Our profiles have values compatible with this recommendation. L-carnitine 
substitution in patients with LCHADD is no longer recommended even when carnitine is low, 
due to the proposed increased generation of long-chain acyl carnitines and arrhythmogenic 
effect from accumulating hydroxylated long-chain acyl CoA esters [30]. None of our patients 
receives carnitine. 
So far, treatment recommendations for disorders of long-chain FAOD are based on expert 
opinion [31]. In 2009, a consensus was published [8], recommending the total dietary fat 
content in LCHADD patients to be 25-30% of total energy intake, with 20-25% as MCT and 
5-10% as LCT. Most of our patients are within the range recommended, however, some MCT 
intake clearly deviates with a median of 62%. Even though not proven in humans so far, on a 
cautious note, this could lead to endogenous fatty acid elongation and hepatopathy [30]. More 
recent data suggest that the fat modification in the diet is less important than the avoidance of 
catabolic state (e.g., infections, physical exertion) [30]. Therefore, fat restriction is becoming 
less strict in clinical practice. It is recommended to give a high energy bolus before exercise 
[12,18]. However, in our cohort only Patient 2 is reported to regularly do that, taking a 
carbohydrate bolus [12]. 
Spiekerkötter et al. reported continual overnight nasogastric tube feeding in 14% of their 
LCHADD patients [8], which is similar to our cohort with 2/14 (14.3%). There are no 
recommendations or indications for NG/PEG in LCHADD. The decision remains a clinical 
one, when patients refuse feedings or the fasting intervals are prolonged. In our opinion, it 
should be an achievable goal to manage children with LCHADD without the need of a 
NG/PEG. 
We tried to use hospitalization number and length in LCHADD patients as an indirect marker 
for metabolic stability. It needs to be said, that LCHADD parents are aware of the need of 
early intervention in case of catabolic episodes. Therefore, short hospitalizations are more 
frequent in this patient group. In summary, for our cohort, except for 3 patients, the first 
hospitalization is the longest (ranging 6 – 91 days, median 27.5), often involving LCHADD 
unrelated problems, like e.g. prematurity. With increasing age, hospitalizations become less 
frequent, indicating less infections with increasing age. 
As anaplerotic substance, heptanoate (C7) supplementation has also been a therapeutic 
approach in LCHADD. So far, studies in animal and cell models [32,33] and small clinical 
trials [11,34,35] have given beneficial proof of impact on hepatic, cardiac and muscular 
symptoms. The longest published observational period is of 61 months [35], there are no 
controlled studies on the long-term effects so far. We can contribute information on C7 
supplementation over a period of almost 10 years. However, we were not able to find a good 
marker to evaluate the impact of heptanoate in the clinical course. Our data (Figure 1 and 
Tables 5 and 6) show that patients stabilize with age, which we attributed to the anaplerotic 
effect of heptanoate, but maybe just came with increasing age (less infections). However, 
there is no obvious difference between patients with and without C7 supplementation. To 
clarify the effect of heptanoate, a placebo-controlled trial should be conducted. 
Conclusion 
Our data show that the outcome of LCHADD can be favourable. Growth and psychomotor 
development is normal in all patients, except in two prematures. Frequency of CK 
measurements decreases with age, which correlates with a decreasing number of hospital 
stays and out-patient visits as well. About 50% of patients develop complications affecting 
different organ systems. However, so far the clinical relevance is low in this pediatric age 
group. There is no relevant difference between the patients treated in the respective centers. 
Concluding from single case reports, anaplerotic therapy with heptanoate should be further 
evaluated, e.g. with conduction of a placebo-controlled trial. 
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